Hot on heels of a pos­i­tive PhI­II, Abl­ynx files $150M IPO; Shire sues Al­ler­gan over dry eye drug ri­val­ry

→ Af­ter watch­ing its Eu­ro­pean share price surge {$ABLX BB} yes­ter­day on pos­i­tive Phase III da­ta, Abl­ynx feels it’s per­fect tim­ing for an IPO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.